Hope for Patients with Solitary Fibrous Tumor: Advances in Sarcoma Care With Dr. Robin Jones
29 days ago
- Molecular confirmation (e.g., NAB2/STAT6) has transformed SFT from a vague diagnosis of exclusion into a well-defined entity, enabling better research and targeted treatments.
- Site-directed therapies like FAP-targeted approaches represent the future of precision oncology, delivering potent agents (chemotherapy or radiation) directly to tumor cells while sparing healthy tissue.
- For rare cancers, clinical trial participation and tissue donation are powerful ways patients can contribute to progress; trials should often be considered early as they can expand, rather than limit, future options.
Comments